This is an aggregated industry headline. Read the full story at STAT News →
Opinion: STAT readers debate blue zones, open-access publishing fees, and more
Keep those letters coming!
By STAT News
· Jun 20, 2026
· via STAT News
Image: STAT News
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineSTAT News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Pfizer's CFO Dave Denton will officially depart in August, leaving SVP of finance Cecile Guegan to take up his…
The WeekFierceBiotech ↗
Zoll Medical, the maker of devices and software focused on cardiopulmonary and respiratory conditions, was sla…
The WeekBriefing
PwC says pharma and life sciences deals topped $65B in Q1 2026, led by big-ticket buys from Sun Pharma and GSK…